Spruce Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-39.0M | $-53.0M | $-47.9M | $-46.2M | $-42.3M | $-29.5M | $-13.1M |
| Depreciation & Amortization | $21.0K | $46.0K | $70.0K | $74.0K | $68.0K | $36.0K | $12.0K |
| Depreciation | — | — | — | — | $23.0K | $5.0K | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.6M | $5.3M | $4.6M | $3.6M | $4.0M | $755.0K | $196.0K |
| Net Cash from Operating Activities | $-33.3M | $-56.0M | $-33.3M | $-41.7M | $-35.9M | $-27.5M | $-12.6M |
| Investing Activities | |||||||
| Capital Expenditures | — | $0 | $7.0K | $8.0K | $93.0K | $74.0K | $4.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | $55.8M | $23.7M | $-79.2M | $-74.0K | $-4.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $43.5M | $-1.6M | $49.1M | $-241.0K | $643.0K | $181.0M | $12.4M |
| Net Change in Cash | — | — | — | — | — | — | — |
| Free Cash Flow | — | $-56.0M | $-33.3M | $-41.7M | $-36.0M | $-27.6M | $-12.6M |